Semaglutide Use in Elderly Obese Patients

Study Overview
=================
Brief Summary
-----------------
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Detailed Description
-----------------
This will be a single center, prospective, open label, randomized and controlled pilot study to investigate the effects of semaglutide addition to a standard weight loss intervention program for 16 weeks on body weight and composition, adipose tissue metabolism and muscle strength compared to the standard weight loss program alone in elderly obese patients. Eligible and qualified patients will be randomized 1:1 in pairs (8 pairs) matched by age and BMI within 5% and by gender to one of two open-label interventions. Priority of enrollment will be to match already existing and non-matched pair(s) before starting new ones. However, participants will not need to wait until they are matched to be enrolled in the study. The two open-label interventions are: Control group: Standard of care weight loss program that includes lifestyle changes and personalized exercise and dietary education. Semaglutide group: semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose. Patients will be instructed on how to inject themselves with the drug and how to increase the dose. During dose escalation, we will be monitoring the subject more extensively (4 weeks and 8 weeks), compared to clinical practice, for any side effects including if they experience any GI side effects, and subjects will be kept at the maximum tolerable dose up to 1mg/week. At the baseline visit, and for all other visits, patients will come fasting (10 -12 hours) to the research center. Patients will visit the research center at 4 weeks (safety visit), 8 weeks and at 16 weeks (final study assessment visit). Blood (about 25 ml), body weight and other vitals, adverse events including hypoglycemia (blood sugar <70 mg/dl) will be collected at all visits. Fat biopsy aspiration, DEXA scans, muscle strength measurement and age-appropriate quality of life questionnaire (Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) will be performed at 0- and 16-weeks visits. All patients will receive instructions at the beginning of the study on weight loss nutritional program and appropriate physical activity to be performed for the next 16 weeks. The program will be based, in-part, on dietary and exercise habits collected at screening visit. For the entire duration of the study, participants will maintain a daily diary to document food and exercise activities to ensure compliance with lifestyle program provided. At the 4- and 8-weeks visits, the daily diary will be reviewed for food and exercise activities, and instructions will be provided again to reinforce intervention. Patients will be provided with glucose meter and glucose strips to measure fingerpick blood glucose. For the entire duration of the study, patients will be asked to measure their blood sugars at least one time after exercise and to record any hypoglycemic events (glucose <70mg/dl) in their diary, Patients will be instructed to record any other untoward side effects like nausea, vomiting, changes in appetite and other experiences in the diary. Patients will be instructed to call the Diabetes Center to speak to a study investigator directly in case of any problem or untoward side effects. they have a question or side effects. Standard of care weight loss program: All patients will be instructed to implement dietary and exercise program for the next 16 weeks and to record their activities on daily food and exercise diary provided. Energy intake should be reduced by 500-750kcal/day. Dietary fat should be reduced to 30% of total energy intake maximally. Meal replacements (if used) will be consumed during breakfast and lunch. Dinner consisted of conventional food and participants will be encouraged to eat fruits and vegetables within their calorie limit. Participants should ingest 1.0-1.5g of protein/kg/day and spread consumption equally throughout the day. A leucine-enriched balanced amino acid supplement can be used. Subjects will be instructed to perform aerobic, muscle-strengthening, flexibility, and balance exercises. Minimally, this should include moderate-intensity aerobic activity for 30 minutes five days per week or vigorous-intensity aerobic activity for 20 minutes three days a week, 10-15 repetitions of 8-10 major muscle group strengthening exercises two or more nonconsecutive days each week, 10 minutes of flexibility activities at least two days a week, and balance exercises three times a week for fall prevention.

Official Title
-----------------
Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment

Conditions
-----------------
Obesity, Aging

Intervention / Treatment
-----------------
* Drug: Semaglutide Pen Injector


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females age: ≥65 years BMI ≥30 Kg/m2 AND waist circumference for women: > 80 cm and for men: > 90 cm Stable body weight (no more than ±3 kg change during the 3 months prior to screening) Able to participate in personalized physical activities and dietary instructions. Participant must be able to read, write, and understand the English language and be able to provide written consent. Exclusion Criteria: Current diagnosis of weight changing condition including cancer, gastrointestinal conditions or eating disorders GLP-1R agonists use within last 6 months Diagnosis of type 1 or 2 diabetes Impaired cognitive function (VA-St. Louis University Mental Survey (VA-SLUMS) score ≤ 19) History of chronic/idiopathic acute pancreatitis Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 Previous surgical treatment for obesity Smoking or use of any nicotine products Use of any medication that could interfere with trial results especially weight management drugs Anticipated change in lifestyle (e.g., dietary, exercise or sleeping pattern) other than provided by the study. Hepatic disease or cirrhosis Aspartate Aminotransferase (AST) > 3X Upper limit of normal (ULN) and/or Alanine aminotransferase (ALT) > 3X ULN Inability to give informed consent History of gastroparesis History of serious hypersensitivity reaction to these agents Alcoholism Patients with retinopathy Participation in any other concurrent interventional clinical trial -

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Single-center, prospective, controlled, randomized and open label study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Semaglutide<br>Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks. | Drug: Semaglutide Pen Injector<br>* semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention<br>* Other names: Ozempic;|
| No Intervention: standard of care only<br>Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in body weight | Difference between arms in change in body weight (in Kg) from baseline (calculated at 16 weeks) | 16 weeks | 
| Change in body composition | Difference between arms in change in body fat from baseline (calculated at 16 weeks) using DEXA | 16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in adipose tissue metabolism | Difference between arms in changes from baseline (calculated at 16 weeks) in RNA expression level (by RT-PCR) of genes related to lipolysis (AGTL and HSL), lipid storage and mobilization (PPARs and PGC-1a) and mitochondrial thermogenesis (β-adrenergic receptors, CPT-1, UCP-1 and UCP-2). | 16 weeks | 
| change in adipose tissue energy expenditure | Difference between arms in mitochondrial basal and maximal oxygen consumption from baseline (calculated at 16 weeks) using the Seahorse XFP energetic flux Analyzer. | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Body composition, Adipose tissue, semaglutide